Kurma Partners

Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Ermium Therapeutics is a Paris-based biotechnology company developing therapies for autoimmune and inflammatory diseases. It focuses on a G protein-coupled receptor pathway centered on CXCR4, described as a master regulator of inflammation that modulates interferon production by plasmacytoid dendritic cells, with a platform aimed at controlling inflammatory responses. The company builds on intellectual property licensed from CNRS and University Paris Descartes through an arrangement with Erganeo, supporting its maturation from academic research. Founded in 2019, Ermium Therapeutics aims to translate its discovery into clinically relevant treatments for autoimmune diseases.

Founded in 2014, DAMAE Medical develops OCTAV, an innovative optical imaging technology that enables dermatologists to obtain high-resolution, non-invasive images of skin tissue similar to histology. This Paris-based medtech company aims to revolutionize skin cancer diagnosis and improve patient outcomes.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Ermium Therapeutics is a Paris-based biotechnology company developing therapies for autoimmune and inflammatory diseases. It focuses on a G protein-coupled receptor pathway centered on CXCR4, described as a master regulator of inflammation that modulates interferon production by plasmacytoid dendritic cells, with a platform aimed at controlling inflammatory responses. The company builds on intellectual property licensed from CNRS and University Paris Descartes through an arrangement with Erganeo, supporting its maturation from academic research. Founded in 2019, Ermium Therapeutics aims to translate its discovery into clinically relevant treatments for autoimmune diseases.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

Founded in 2014, DAMAE Medical develops OCTAV, an innovative optical imaging technology that enables dermatologists to obtain high-resolution, non-invasive images of skin tissue similar to histology. This Paris-based medtech company aims to revolutionize skin cancer diagnosis and improve patient outcomes.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.